Peptide Research Library
Peptide Research Library
Plain-English guides to peptide and research-compound literature, built around primary studies, model labels, practical limitations and responsible U.S. laboratory procurement.
Useful enough for researchers. Clear enough for everyone else.
Peptide search results often flatten very different kinds of evidence into a single claim. A cell experiment, an animal study and a controlled human trial do not answer the same question. These guides keep those layers visible.
Each page explains what a compound is, why laboratories examine it, what selected primary papers reported, what remains uncertain and what a qualified buyer should verify before sourcing research material in the USA.
Explore the evidence map
Repair & Immune Signaling
7 guides
BPC-157
Explore what BPC-157 studies report in tendon cells, endothelial systems, and animal injury models—and what those studies do not establish in people.
Mixed evidence · 4 sources
TB-500 & Thymosin Beta-4
Understand what thymosin beta-4 research shows, where limited human eye studies fit, and why TB-500 product identity cannot be assumed from a label.
Mixed evidence · 4 sources
KPV
Review how KPV has been studied in cells and mouse inflammation models, including PepT1 transport, NF-κB signaling, and targeted delivery systems.
Mixed evidence · 4 sources
LL-37
See why LL-37 is more than an antimicrobial peptide: primary studies cover membrane activity, epithelial biology, vascular signaling, and self-DNA sensing.
Mixed evidence · 4 sources
Thymosin Alpha-1
Explore why thymosin alpha-1 is better described as an immune modulator than an immune booster, with cell, animal, and randomized human evidence.
Mixed evidence · 5 sources
VIP
Review VIP signaling through VPAC receptors, its neuroimmune research context, and why animal disease models do not establish human treatment effects.
Mixed evidence · 5 sources
ARA-290
Trace ARA-290 from helix-B peptide design to animal injury models and small cibinetide trials, with careful treatment of surrogate outcomes.
Mixed evidence · 5 sources
Neuropeptide & Endocrine Signaling
8 guides
Semax
Semax is an ACTH(4-7)-Pro-Gly-Pro heptapeptide studied mainly in rat brain and cell models. This guide separates mechanistic signals from unproven human outcomes.
Mixed evidence · 4 sources
Selank
Selank is a tuftsin-derived heptapeptide studied largely in rat neurobiology. The research suggests multiple pathways but does not prove broad human outcomes.
Mixed evidence · 5 sources
Epitalon
Epitalon is the tetrapeptide Ala-Glu-Asp-Gly. Most direct evidence is cell-based, so telomerase findings should not be translated into human longevity promises.
Mixed evidence · 5 sources
Adamax
Adamax did not resolve to compound-specific primary evidence in the PubMed audit. The responsible story is identity verification, not borrowed Semax claims.
Limited compound-specific evidence · 3 sources
Kisspeptin
Kisspeptin activates KISS1R upstream of GnRH. Human studies show acute hormone responses, but peptide form and repeated-exposure dynamics limit broad conclusions.
Human research · 4 sources
CJC-1295
Published CJC-1295 is a DAC-modified GHRH analog designed to bind albumin. The direct evidence base is small and should not be reassigned to no-DAC products.
Mixed evidence · 3 sources
Ipamorelin
Ipamorelin is a GHSR agonist, not a GHRH analog. Preclinical and biomarker signals exist, but the controlled phase 2 efficacy trial was negative.
Mixed evidence · 4 sources
GHRH-T44 / Sermorelin
GHRH(1-44) and sermorelin/GHRH(1-29) act in the same receptor system but are different molecules. A T44 label needs sequence-level verification.
Human research · 4 sources
Melanocortin Signaling
3 guides
PT-141 / Bremelanotide
PT-141 is bremelanotide, a cyclic melanocortin agonist with controlled human trials. Those trials do not authenticate or authorize use of a research-market vial.
Human research · 4 sources
Melanotan I
Melanotan I shares the NDP-alpha-MSH lineage with afamelanotide, but early research material and later pharmaceutical implants are not interchangeable products.
Human research · 4 sources
Melanotan II
Melanotan II is a cyclic, nonselective melanocortin agonist. Its broad receptor biology and very small human studies make simple benefit claims scientifically misleading.
Mixed evidence · 5 sources
Metabolic & Cell Signaling
8 guides
Metabolic Research Compounds
A model-aware map of MOTS-c, AICAR, NAD+, SLU-PP-332, FOXO4-DRI, GHK-Cu, Glow blends, and Lipo-C research materials.
Mixed evidence · 3 sources
MOTS-c
What researchers have observed about MOTS-c in cells, mice, and exercise studies—and what those models cannot establish.
Mixed evidence · 3 sources
AICAR
A model-aware review of AICAR, AMPK-associated experiments, AMPK-independent effects, and a null human trial in a specific surgical setting.
Mixed evidence · 4 sources
NAD+
A precise guide to NAD+ biology, compartmentalized pools, precursor studies, and the limits of biomarker-based claims.
Mixed evidence · 4 sources
SLU-PP-332
What SLU-PP-332 studies measured in reporter systems, muscle cells, mice, and donor-derived myoblast cultures—and what remains unknown.
Mixed evidence · 3 sources
FOXO4-DRI
Foundational and opposing FOXO4-DRI evidence, with D-retro-inverso identity and model limits made explicit.
Mixed evidence · 3 sources
GHK-Cu & Glow Blend
A component-by-component evidence map for GHK-Cu and nonstandardized Glow blends, including null findings and mixture-specific QC.
Mixed evidence · 5 sources
Lipo-C
A formula-first guide to Lipo-C components, nutrient research, deficiency-model limits, and mixture-specific documentation.
Mixed evidence · 3 sources
Laboratory Procurement & Quality
2 guides
How to Read a Peptide COA
Turn a COA from a decorative badge into a traceable, method-specific piece of lot evidence.
Mixed evidence · 3 sources
Purity, Identity, and Content
A plain-language analytical guide for separating what is present, how clean the chromatogram looks, and how much target analyte is in a container.
Mixed evidence · 3 sources
Every study is labeled before it is summarized.
Our pages identify the experimental model, describe the design in ordinary language and pair each reported result with a limitation. That prevents early research from being presented as a clinical answer.